Deunoxavir
Small moleculeexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
3
Phase 4
0
Earliest trial started Dec 7, 2022 (NCT06342921)
Timeline
Indications
Mechanism of action
- Influenza virusINHIBITOR
Influenza virus inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06589635 | Phase 1 | Jul 16, 2024 | Government of China |
| NCT06507813 | Phase 3 | Jun 28, 2024 | Government of China |
| NCT06348576 | Phase 3 | May 20, 2024 | Addpharma Inc., Korea University |
| NCT06485401 | Phase 1 | Mar 14, 2024 | Government of China |
| NCT06428903 | Phase 1 | Mar 12, 2024 | Government of China |
| NCT06360796 | Phase 1 | Nov 24, 2023 | Government of China |
| NCT06342921 | Phase 2/Phase 3 (Phase 3) | Dec 7, 2022 | Government of China |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 6 | 6 | 2 | 2022 |
| Addpharma Inc. | For profit | 1 | 1 | 1 | 2024 |
| Korea University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1